Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

Large variations found in survival from blood cancers between European countries

Dr Milena Sant - Istituto Nazionale Tumori, Milan, Italy

Large variations found in survival from blood cancers between European countries ( Dr Milena Sant - Istituto Nazionale Tumori, Milan, Italy )

CheckMate 025 trial results: Nivolumab versus everolimus in pre-treated...

Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA

CheckMate 025 trial results: Nivolumab versus everolimus in pre-treated advanced kidney cancer ( Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA )

Everolimus for non-functional neuroendocrine tumours

Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA

Everolimus for non-functional neuroendocrine tumours ( Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA )

Nivolumab improves overall survival for advanced kidney cancer

Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA

Nivolumab improves overall survival for advanced kidney cancer ( Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA )

METEOR trial results: Cabozantinib improves advanced kidney cancer survival

Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

METEOR trial results: Cabozantinib improves advanced kidney cancer survival ( Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Atrial fibrillation in CLL patients on ibrutinib

Prof Florence Cymbalista – University of Paris, Paris, France

Atrial fibrillation in CLL patients on ibrutinib ( Prof Florence Cymbalista – University of Paris, Paris, France )

Circulating levels of tumour DNA in plasma may help monitor treatment response...

Dr Constantine Tam – Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating levels of tumour DNA in plasma may help monitor treatment response and resistance in CLL ( Dr Constantine Tam – Peter MacCallum Cancer Centre, Melbourne, Australia )

Tumour specific immunotherapy in CLL

Prof Catherine Wu - Harvard Medical School, Boston, USA

Tumour specific immunotherapy in CLL ( Prof Catherine Wu - Harvard Medical School, Boston, USA )

Highlights from iwCLL 2015

Prof Stephen Mulligan - CLL Australian Research Consortium, Sydney, Australia

Highlights from iwCLL 2015 ( Prof Stephen Mulligan - CLL Australian Research Consortium, Sydney, Australia )

Cytogenetic and proteomic prognostic markers of CLL

Dr Lauren Thurgood - Flinders University, Adelaide, South Australia

Cytogenetic and proteomic prognostic markers of CLL ( Dr Lauren Thurgood - Flinders University, Adelaide, South Australia )

Predicting progression and survival in CLL

Prof Jonathan Strefford - University of Southampton, Southampton, UK

Predicting progression and survival in CLL ( Prof Jonathan Strefford - University of Southampton, Southampton, UK )

Phase I study of duvelisib in patients with relapsed or refractory CLL

Dr Susan O’Brien – University of California, Irvine, California, USA

$Phase I study of duvelisib in patients with relapsed or refractory CLL ( Dr Susan O’Brien – University of California, Irvine, California, USA )$

More from ecancer